4
Impact Report
Being the Voice
BCNA’s policy and advocacy purpose is to improve the lives and outcomes of all those affected by breast cancer in Australia. Your donations helped support our advocacy work, which not only assists those who reach out to BCNA but ALL those affected by breast cancer across Australia.
Being diagnosed with cancer during my pregnancy, I would have done anything to help my chances of survival. I would not have been able to afford Keytruda without crowdfunding. – BCNA member We know that Keytruda can increase the survival rates of triple negative breast cancer patients. We need to ensure that every person can afford to access to this lifesaving and life-extending medication. – BCNA member Access to new drugs and treatments In 2023, two key breast cancer drugs were listed on the Pharmaceutical Benefits Scheme (PBS) following our advocacy. • Enhertu (trastuzumab deruxtecan) for metastatic HER2-positive breast cancer. • Keytruda (pembrolizumab) for metastatic triple negative breast cancer and early triple negative breast cancer. Without government subsidy, life-saving and life-prolonging treatment options remain out of reach for many. BCNA continues to work with consumers and clinicians to identify emerging new treatments, and advocates to both industry and the government for timely consideration of these treatments for subsidy.
2023 QUICK FACTS:
216 stakeholder engagements and 74 leadership and capacity- building activities in the breast cancer, cancer and wider health sectors
73 requests for consumer involvement in research and other projects Nine submissions made in support of subsidised drugs, devices, and tests
Made with FlippingBook - professional solution for displaying marketing and sales documents online